Overview

L-Carnitine as an Osmo-metabolic Agent for Peritoneal Dialysis

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
A major challenge of peritoneal dialysis (PD) therapy is the development of glucose-sparing strategies able to provide an efficacious ultrafiltration (UF) profile. Study hypothesis is to evaluate the possibility to formulate PD solutions containing L-carnitine as an osmotic agent to partially replace glucose.
Phase:
Phase 2
Details
Lead Sponsor:
Iperboreal Pharma Srl